Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Cancer Immunol Immunother. 2016 Aug 31;65(11):1353–1364. doi: 10.1007/s00262-016-1893-7

Fig. 4. MDSC levels are associated with overall survival.

Fig. 4

Circulating levels of total (HLADR-,CD33+), granulocytic (HLADR-,CD33+,CD11b+,CD15+) or monocytic (HLADR-,CD33+,CD11b+,CD14+) MDSC were measured by flow cytometry prior to or after completion of cycle 1 of treatment. (a) Patient samples analyzed before (Pre) and after 1 cycle (n=19) and (b) absolute change in MDSC by cohort group, calculated as %MDSC Pre- minus %MDSC Post-Cycle 1. (c) Pre-treatment MDSC and (d) Post-Cycle 1 MDSC levels stratified by overall survival at 150 days. Dot plots with medians and interquartile range are shown